[1] Bernardo GM, Keri RA. FOXA1: a transcription factor with parallel functions in development and cancer[J]. Bioscience reports, 2012, 32(2): 113130.
[2] Abe Y, Ijichi N, Ikeda K, et al. Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells[J]. Cancer Sci, 2012, 103(4): 806812.
[3] Hu Q, Luo Z, Xu T, et al. FOXA1: a promising prognostic marker in breast cancer[J]. Asian Pac J Cancer Prev, 2014, 15(1): 1116.
[4] Song J, Li Z, Tong X, et al. Genomewide identification and characterization of Fox genes in the silkworm, Bombyx mori[J]. Funct Integr Genomics, 2015, In press.
[5] Liu N, Niu Y. Transcription factor Forkheadbox A1 and breast cancer[J]. Zhonghua Bing Li Xue Za Zhi, 2010, 39(2): 136139.
[6] Caravaca JM, Donahue G, Becker JS, et al. Bookmarking by specific and nonspecific binding of FoxA1 pioneer factor to mitotic chromosomes[J]. Genes Dev, 2013, 27(3): 251260.
[7] Stott SR, Metzakopian E, Lin W, et al. Foxa1 and foxa2 are required for the maintenance ofdopaminergic properties in ventral midbrain neurons at late embryonic stages[J]. J Neurosci, 2013, 33(18): 80228034.
[8] Gao N, Le Lay J, Qin W, et al. Foxa1 and Foxa2 maintain the metabolic and secretory features of the mature betacell[J]. Mol Endocrinol, 2010, 24(8): 15941604.
[9] Li Z, Tuteja G, Schug J, et al. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer[J]. Cell, 2012, 148(12):7283.
[10] Theodorou V, Stark R, Menon S, et al. GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility[J]. Genome Res, 2013, 23(1): 1222.
[11] Qiu M, Bao W, Wang J, et al. FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer[J]. BMC Cancer, 2014, 14: 78.
[12] Guo W, Keener AL, Jing Y, et al. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells[J]. Prostate, 2015, 75(9):976987.
[13] DeGraff DJ, Clark PE, Cates JM, et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation[J]. PLoS One, 2012, 7(5): e36669.
[14] Wang J, Bao W, Qiu M, et al. Forkheadbox A1 suppresses the progression of endometrial cancer via crosstalk with estrogen receptor alpha[J]. Oncol Rep, 2014, 31(3): 12251234.
[15] Bernardo GM, Lozada KL, Miedler JD, et al. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis[J]. Development, 2010, 137(12): 20452054.
[16] Barriere G, Fici P, Gallerani G, et al. Epithelial Mesenchymal Transition: a doubleedged sword[J]. Clin Transl Med, 2015, 4: 14.
[17] Liu YN, Lee WW, Wang CY, et al. Regulatory mechanisms controlling human Ecadherin gene expression[J]. Oncogene, 2005, 24(56): 82778290.
[18] Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelialtomesenchymal transition in pancreatic cancer[J]. Cancer Res, 2010, 70(5): 21152125.
[19] Liu YN, AbouKheir W, Yin JJ, et al. Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor betainitiated prostate cancer epithelialmesenchymal transition[J]. Mol Cell Biol, 2012, 32(5): 941953.
[20] Jin HJ, Zhao JC, Ogden I, et al. Androgen receptorindependent function of FoxA1 in prostate cancer metastasis[J]. Cancer Res, 2013, 73(12): 37253736.
[21] Sasaki. Forkhead box A1 transcriptional pathway in KRT7expressing esophageal squamous cell carcinomas with extensive lymph node metastasis[J]. Int J Oncol, 2010, 36(2):321330.
[22] Lin YC, Lee YC, Li LH, et al. Tumor suppressor SCUBE2 inhibits breastcancer cell migration and invasion through the reversal of epithelialmesenchymal transition[J]. J Cell Sci, 2014, 127(Pt 1): 85100.
[23] Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours [J]. Nature, 2000, 406(6797): 747752.
[24] Albergaria A, Paredes J, Sousa B, et al. Expression of FOXA1 and GATA3 in breast cancer: the prognostic significance in hormone receptornegative tumours[J]. Breast Cancer Res, 2009, 11(3): R40.
[25] Kawase M, Toyama T, Takahashi S, et al. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptorpositive breast cancer[J]. Breast Cancer, 2015, 22(3):308316.
[26] Thorat MA, Marchio C, Morimiya A, et al. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol, 2008, 61(3): 327332. |